Back to top
more

RxSight (RXST)

(Delayed Data from NSDQ)

$57.89 USD

57.89
398,128

-1.45 (-2.44%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $57.89 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Strength Seen in RxSight, Inc. (RXST): Can Its 9.6% Jump Turn into More Strength?

by Zacks Equity Research

RxSight, Inc. (RXST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Alphatec (ATEC) Surges 8.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

RxSight, Inc. (RXST) delivered earnings and revenue surprises of 19.23% and 7.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will RxSight, Inc. (RXST) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

RxSight, Inc. (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 7.55% and 1.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why RxSight, Inc. (RXST) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Tirthankar Chakraborty headshot

4 Best Breakout Stocks to Buy Now for Superlative Returns

by Tirthankar Chakraborty

CymaBay Therapeutics (CBAY), RxSight (RXST), UWM (UWMC) & Remitly Global (RELY) have been selected as the breakout stocks for today.

How Much Upside is Left in RxSight, Inc. (RXST)? Wall Street Analysts Think 25.69%

by Zacks Equity Research

The consensus price target hints at a 25.7% upside potential for RxSight, Inc. (RXST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Intra-Cellular Therapies (ITCI) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.

Is RxSight (RXST) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how RxSight, Inc. (RXST) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Does RxSight, Inc. (RXST) Have the Potential to Rally 43% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 42.7% upside potential for RxSight, Inc. (RXST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 45% Upside in RxSight, Inc. (RXST): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for RxSight, Inc. (RXST) points to a 45% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.

RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

RxSight, Inc. (RXST) delivered earnings and revenue surprises of 12.86% and 19.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sensus Healthcare, Inc. (SRTS) Q3 Earnings Lag Estimates

by Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -8.33% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RxSight, Inc. (RXST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

RxSight, Inc. (RXST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

RxSight, Inc. (RXST) delivered earnings and revenue surprises of 26.47% and 0.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?